Regulus Therapeutics Inc.
RGLS
शेयरों में रैंक
#17214
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
शेयर मूल्य
$8.16
अंतिम समन्वयन: 2025-06-26
मार्केट कैप
$234.57M
बदलाव (1 दिन)
0.00%
बदलाव (1 वर्ष)
-56.96%
देश
US
व्यापार Regulus Therapeutics Inc. (RGLS)
श्रेणी
Healthcare
Regulus Therapeutics Inc. (RGLS) के लिए स्टॉक मूल्य इतिहास
दिन का सबसे उच्च समापन मूल्य: $18.90 (2024-08-01 को)
दिन का सबसे निम्न समापन मूल्य: $25.97 (2018-04-01 को)
दिन का सबसे निम्न समापन मूल्य: $25.97 (2018-04-01 को)
Regulus Therapeutics Inc. के स्टॉक मूल्य का इतिहास 2018 से 2026 तक
प्रत्येक वर्ष के अंत में स्टॉक मूल्य प्रदर्शन
| वर्ष | प्रदर्शन |
|---|---|
| 2024 | 115.52% |
| 2023 | 128.77% |
| 2022 | -59.49% |
| 2021 | -66.20% |
| 2020 | -18.96% |
| 2019 | 28.12% |
| 2018 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के स्टॉक मूल्य
| कंपनी | स्टॉक मूल्य | परिवर्तन 1व% | देश |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $757.97 | 7.73% |
CH
|
